Skip to main content
SpringerLink
Log in

Analisi costo-efficacia dell’impiego precoce di lisinopril nei pazienti con infarto miocardico acuto

Risultati del trial GISSI-3

  • Published:
PharmacoEconomics Italian Research Articles

Summary

The cost effectiveness of early treatment with lisinopril in acute myocardial infarction (MI) was estimated using survival and cost data gathered prospectively during the hospitalisation of the overall population of patients enrolled in the third study of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto (GISSI-3), which assessed the efficacy of early (within 24 hours) treatment with an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) for 6 weeks in a group of 19 394 relatively unselected patients with acute MI. A statistically significant reduction in 6-week mortality was achieved among patients treated with lisinopril when compared with patients allocated to the control group (absolute reduction in mortality: 7.5 ± 3.6 lives saved per 1000 treated patients). The comparative cost-effectiveness ratio for the use of lisinopril, expressed as cost per additional survivor among patients randomised to receive lisinopril, was $US2080 per life saved (1993 values). The sensitivity analysis conducted to examine the effects of varying the estimated absolute reduction in mortality throughout its 95% confidence interval, which ranged from 14.6 to 0.4 lives saved per 1000 treated patients, showed that the cost-effectiveness ratios consequently vary from $US1121 to $US40 910 per life saved. The cost effectiveness of early treatment with lisinopril of a relatively unselected population of patients with acute MI compares very favourably with that of other therapies judged to be worthwhile by the medical community.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Bibliografia

  1. Detsky AS, Naglie IG. A clinician’s guide to cost-effectiveness analysis. Ann Intern Med 1990; 113: 147–54

    PubMed  CAS  Google Scholar 

  2. Powe NR, Griffiths RI. The clinical-economic trial: promise, problems and challenges. Control Clin Trials 1995; 16: 377–97

    Article  PubMed  CAS  Google Scholar 

  3. Drummond MF, Davies LM. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess in Health Care 1991; 7: 561–73

    Article  CAS  Google Scholar 

  4. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22

    Google Scholar 

  5. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after myocardial infarction: the GISSI-3 Trial. J Am Coll Cardiol 1996; 27: 337–44

    Google Scholar 

  6. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85

    Article  Google Scholar 

  7. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686–7

    Article  Google Scholar 

  8. Latini R, Maggioni AP, Flather M, et al. ACE-inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation 1995; 32: 3132–7

    Article  Google Scholar 

  9. ACE-inhibitor Myocardial Infarction Collaborative Group. Evidence for early beneficial effect of ACE-inhibitors started within the first day in patients with acute myocardial infarction: results of a systematic overview among about 100,000 randomized patients. Circulation 1996; 94: 1–90

    Article  Google Scholar 

  10. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarction. Am J Cardiol 1992; 70: 62C–9C

    Google Scholar 

  11. Decreto Ministero della Sanità del 14-12-1994. Tariffe delle prestazioni di assistenza ospedaliera: supplemento della Gazzetta Ufficiale del 24-12-1994. Rome: Iberia Dello Stato, 1994

  12. L’Informatore Farmaceutico 53∘ed. Organizzazione Editoriale Medico Farmaceutica. Milan: Organizzazione Editoriale Medico, 1993

  13. Gruppo di lavoro DURG-Italia. La lista delle DDD del DURG-Italia. G Ital Farm Clin 1995; 9: 83–137

    Google Scholar 

  14. Briggs A, Sculper M, Buxton M. Uncertainty in economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95–104

    Article  PubMed  CAS  Google Scholar 

  15. Drummond MF, Stoddart GL. Economic analysis and clinical trials. Control Clin Trials 1984; 5: 115–28

    Article  PubMed  CAS  Google Scholar 

  16. Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care 1992; 30: 231–43

    Article  PubMed  CAS  Google Scholar 

  17. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82

    Article  Google Scholar 

  18. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418–24

    Article  PubMed  CAS  Google Scholar 

  19. Mark DB. Economic analysis methods and endpoints. In: Califf RM, Mark DB, Wagner GS, editors. Acute coronary care in the thrombolytic era. 2nd ed. St Louis: Mosby-Year Book, 1995: 167–82

    Google Scholar 

  20. Michel BC, Al MJ, Remme WJ, et al. Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands. Eur Heart J 1996; 17: 731–40

    Article  PubMed  CAS  Google Scholar 

  21. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996; 78: 409–14

    Article  PubMed  CAS  Google Scholar 

  22. Johannesson M, Jönsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332–6

    Article  PubMed  CAS  Google Scholar 

  23. Naylor D. Cost-effectiveness analysis: are the outputs worth the inputs? ACP J Club 1996; 124: A12–4

    PubMed  CAS  Google Scholar 

  24. Armentano R, Favaloro RG. Is the use of t-PA as compared with streptokinase cost effective? N Engl J Med 1995; 333: 1009–10

    Article  PubMed  CAS  Google Scholar 

  25. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7

    Article  PubMed  CAS  Google Scholar 

  26. Rogers S. Prevention of coronary heart disease with pravastatin [letter]. N Engl J Med 1996; 334: 1333

    Article  PubMed  CAS  Google Scholar 

  27. McMurray JJV, McGuire A, Davie AP, et al. Cost-effectiveness of different ACE-inhibitor treatment scenarios post-myocardial infarction. Eur Heart J 1997; 18: 1411–5

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Ricerca Cardiovascolare, Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157, Milano, Italia

    Maria Grazia Franzosi, A. P. Maggioni, E. Santoro, G. Tognoni & E. Cavalieri

Authors
  1. Maria Grazia Franzosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. P. Maggioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Tognoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Cavalieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Grazia Franzosi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Franzosi, M.G., Maggioni, A.P., Santoro, E. et al. Analisi costo-efficacia dell’impiego precoce di lisinopril nei pazienti con infarto miocardico acuto. Pharmacoeconomics-Ital-Res-Articles 2, 43–52 (2000). https://doi.org/10.1007/BF03320573

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03320573

Search

Navigation